A Case of Cytokine Release Syndrome Induced by Avelumab and Axitinib Combination Therapy for Metastatic Renal Cell Carcinoma.

INTRODUCTION

Cytokine release syndrome (CRS) is a rare immune-related adverse event of immune checkpoint inhibitors (ICIs). At present, its association with avelumab-axitinib therapy for renal cell carcinoma (RCC) has yet to be reported. Differentiating early CRS from an infusion-related reaction (IRR) is clinically challenging, particularly in the context of concurrent coronavirus disease (COVID-19).

CASE PRESENTATION: A 76-year-old woman with recurrent RCC developed chills, hypotension requiring norepinephrine, and hypoxemia within hours of her first avelumab infusion. Despite IRR-directed therapy, the patient's condition worsened. Laboratory evaluation revealed markedly elevated Interleukin-6 with normal C-reactive protein, elevated procalcitonin levels, and negative cultures, supporting cytokine-driven inflammation. COVID-19 was detected and the clinical trajectory suggested CRS amplification. The patient was successfully treated with corticosteroids and tocilizumab.

CONCLUSION

This is the first report of CRS associated with avelumab-axitinib therapy in RCC and highlights the importance of early recognition and distinction from IRR, especially when COVID-19 coexists.